Breakfast or not? study tests new pill for brain disorders
NCT ID NCT07292233
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study looks at how taking a new extended-release tablet (LY03020) with or without food changes the way the body absorbs the drug. The medicine is being developed for schizophrenia and psychosis in Alzheimer's disease. Sixteen healthy adults will take the drug twice—once after eating and once on an empty stomach—to compare the effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing AnDing Hospital Capital Medical University
Beijing, China
Conditions
Explore the condition pages connected to this study.